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Background: Hypertensive disorders represent the major cause of maternal morbidity in middle income countries.
The main objective of this study was to identify the prevalence and factors associated with severe maternal
outcomes in women with severe hypertensive disorders.
Methods: This was a cross-sectional, multicenter study, including 6706 women with severe hypertensive disorder
from 27 maternity hospitals in Brazil. A prospective surveillance of severe maternal morbidity with data collected
from medical charts and entered into OpenClinica®, an online system, over a one-year period (2009 to 2010).
Women with severe preeclampsia, severe hypertension, eclampsia and HELLP syndrome were included in the study.
They were grouped according to outcome in near miss, maternal death and potentially life-threatening condition.
Prevalence ratios and 95% confidence intervals adjusted for cluster effect for maternal and perinatal variables and
delays in receiving obstetric care were calculated as risk estimates of maternal complications having a severe
maternal outcome (near miss or death). Poisson multiple regression analysis was also performed.
Results: Severe hypertensive disorders were the main cause of severe maternal morbidity (6706/9555); the
prevalence of near miss was 4.2 cases per 1000 live births, there were 8.3 cases of Near Miss to 1 Maternal Death
and the mortality index was 10.7% (case fatality). Early onset of the disease and postpartum hemorrhage were
independent variables associated with severe maternal outcomes, in addition to acute pulmonary edema, previous
heart disease and delays in receiving secondary and tertiary care.
Conclusions: In women with severe hypertensive disorders, the current study identified situations independently associated
with a severe maternal outcome, which could be modified by interventions in obstetric care and in the healthcare
system. Furthermore, the study showed the feasibility of a hospital system for surveillance of severe maternal morbidity.
Keywords: Organ dysfunction, Organ failure, Severe preeclampsia, Eclampsia, Maternal mortality, Maternal morbidityBackground
It has been estimated that hypertensive disorders (HD)
in pregnancy cause 50.000 maternal deaths (MD) annu-
ally in the world and the vast majority of them occur in
low-income or middle-income countries [1]. The main
cause of MD in Latin America and in the Caribbean is* Correspondence: cecatti@unicamp.br
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reproduction in any medium, provided the orHD, accounting for approximately one-fourth of the
total number of deaths [2].
In high-income countries, such as the United States,
the prevalence of hospital admissions due to HD in
pregnancy increased significantly between 1998 and 2006,
rising from 67.2 to 81.4 per 1.000 deliveries over that time
period [3]. In Canada, HD is the third cause of antenatal
hospitalization, with little variation in rates for a 10-year
period, from 15.4 per 1000 deliveries in 1991 to 11.3 per
1000 deliveries in 2001 [4].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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times, e.g. placental abruption, thrombocytopenia, dissem-
inated intravascular coagulation, acute pulmonary edema,
cerebrovascular disorders and other conditions, in com-
parison to women without hypertension [3,5,6]. The con-
trast between low or very low maternal mortality ratios
(MMR) in high-income countries, compared to low-
income or middle-income countries with high MMR has
been attributed to the quality of obstetric care, patient ac-
cess to hospitalization, qualification of health professionals
and structural resources, including the input and availabil-
ity of intensive care units [7-9].
In this context, the United Nations has recognized that
quality of care is of central importance in the strategy to
improve maternal and infant health [10]. In the last two
decades, there has been increasing interest in the study
of severe maternal morbidity (SMM) cases, including its
more severe component - the maternal near miss (NM),
as a supplementary method to audits and inquiries on
MD [11-13]. The investigation of NM could furnish
more details about factors contributing to both mortality
and SMM [10-14] and may be a reference for quality as-
sessment of obstetric care. Nevertheless, in the literature
there is still a wide variety of criteria used to identify
maternal NM cases [14].
In 2009, the WHO defined concepts and standardized
criteria to identify NM cases, after the identification of
organ dysfunction and/or failure as the main determinants
of severity. Clinical signs, laboratory tests and manage-
ment interventions were used, all capable of diagnosing
organ dysfunction or failure [15]. These criteria were pre-
viously validated by the WHO Working Group following
markers of dysfunction and total maximum SOFA
(sequential organ failure assessment) score, applied to an
obstetric population [15-17].
This study is proposed due to the high association be-
tween hypertensive disorders in pregnancy and severe
obstetric/clinical complications, resulting in high rates
of severe maternal outcomes (SMO). In addition, there
are only few studies to date focused on severe morbidity
as proposed by the WHO [15]. Therefore, the purpose
of the current study was to identify the prevalence and
factors associated with the risk of severe maternal out-
comes (NM and MD) in a female population with severe
hypertensive disorders (severe preeclampsia, eclampsia,
severe hypertension and HELLP syndrome) [18].
Method
Study population
This was a multicenter study, based on 27 referral ma-
ternity hospitals located in the five Brazilian regions
participating in the Brazilian Network for Surveillance
of Severe Maternal Morbidity [19]. Local investigators
from each participating maternity hospital carried out aprospective surveillance with data routinely collected,
but only after discharge (or death) in all women admit-
ted to hospital during the study period because of a
SMM episode. We defined a SMM condition as any case
that could be classified, according to the WHO recom-
mendations [15], as a Potentially Life Threatening con-
dition or a severe maternal outcome (Near Miss or
Maternal Death). Data were first collected in specific
forms and then entered into the online OpenClinica®
platform. Details on the original study methods are
already published elsewhere [19,20].
Identification of cases
This is an analysis of SMM cases due to severe hyperten-
sive disorders among the total number of SMM during
pregnancy and postpartum period, managed by these ma-
ternity hospitals, over a 12-month period, from July 2009
to June 2010. For this specific analysis focusing on severe
hypertensive disorders, we included women diagnosed
with: severe hypertension and hypertensive emergency:
blood pressure (BP) level ≥ 160/110 mmHg or hyperten-
sive peak of any value, associated with symptoms or signs
of target organ lesion; severe preeclampsia: BP ≥ 160/
110 mmHg and/or symptomatology of target organ com-
promise and/or proteinuria determined by dipstick ++ or
over 24 hours ≥ 2 g; and/or oliguria < 30 ml/hour and/or
thrombocytopenia < 100.000 mm3; eclampsia: presence of
seizures in a woman with preeclampsia; and HELLP syn-
drome: presence of at least one parameter: LDH ≥600U/L;
bilirubin ≥1.2 mg/dl; AST ≥70U/L; or thrombocytope-
nia < 100.000 mm3 [18,20]. .The cases were classified ac-
cording to the WHO criteria into PLTC and severe mater-
nal outcome (NM/MD) [15]. All these definitions and
criteria were included in the correspondent manual of op-
eration of the study [20].
Variables
The variables studied were: socio demographic charac-
teristics, obstetric history, history of previous disease, pa-
tient access to obstetric care, mode of delivery, perinatal
results, clinical complications and advanced life support
interventions (excluding all those already defined as near
miss criteria [15]), in addition to identification of the
“three delays” according to the model originally developed
by Taddeus and Maine [21]. The questionnaire has a spe-
cific session where delays are explored separately for each
of the three phases, with several possibilities for each one
being directly asked. Besides that, a rigorous system of
data checking was developed by the coordinating center
in order to gather more reliable information, as already
described [20]. The adequacy of the number of prenatal
care visits according to gestational age was based on the
Brazilian Ministry of Health recommendation that at least
one visit should be performed during the first trimester,
Table 1 Women with hypertensive disorders (HD) and
non HD among those with severe maternal morbidity or
death and their correspondent health indicators
Condition PLTC NM MD Total
n (%) n (%) n (%) N (%)
HD 6315 (73) 349 (45) 42 (30) 6706 (70)
Non HD 2330 (27) 421 (55) 98 (70) 2849 (30)
Total 8645 (100) 770 (100) 140 (100) 9555 (100)
PLTC: Potentially life-threatening condition; NM: near miss; MD: maternal death;
Live births = 82,144.
MNM prevalence ratio for HD = 4.2 NM/1000LB (for non HD = 5.1 NM/1000LB).
Severe Maternal Outcome Ratio (SMOR) for HD = 4.76/1000LB (for non
HD = 6.32/1000LB).
Maternal near miss: Maternal death ratio for HD = 8.3NM:1MD (for non
HD = 4.3NM:1MD).
Mortality index for HD = 42MD/391 = 10.7% (for non HD = 18.9%).
MMR = 51.1MD/100.000 LB for HD (for non HD = 119.3 MD/100.000LB).
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ter of pregnancy. The variables were selected, among all
others available in the database, after some exploratory
analysis and because they were supposed to be the most
important ones for the topic of care to women with severe
hypertensive disorders during pregnancy.
Analysis
Initially, the health indicators for severe maternal mor-
bidity, namely Maternal Near Miss Ratio (MNMR),
Severe Maternal Outcome Ratio (SMOR), Maternal Near
Miss to Maternal Death Ratio (NM:MD ratio), Mortality
Index (a proxy to case fatality ratio) and Maternal Mor-
tality Ratio (MMR) were calculated as recommended by
WHO [15]. Bivariate analysis was then performed to
identify factors (predictors) associated with severe ma-
ternal outcomes (maternal near miss or maternal death)
by estimating prevalence ratios (PR) and their respective
95% confidence intervals (CI), adjusted for cluster effect
(maternity hospitals or centers), although the intraclass
correlation coefficients were very low for the majority of
variables studied as desired and already described [22].
Maternal complications and procedures used for man-
agement other than those already used for near miss
case definition according to WHO were described com-
paratively among women from both groups, with differ-
ences assessed with Chi-square test. Additionally the
risks of perinatal results were also estimated for women
who had severe maternal outcomes (near miss or death)
with adjusted prevalence ratios (PR) and their respective
95% confidence intervals (CI). Finally, Poisson multiple
regression analysis was performed, also adjusted by clus-
ter and all other predictors. A 95% confidence level was
used (with a 5% level of significance) and the software
used for analyses were SPSS® version 17 (SPSS, Chicago,
IL, USA) and Stata® version 7.0 (StataCorp, College
Station, TX, USA).
Ethics statement
The study was approved by each local Institutional Review
Board and by the National Human Research Ethics
Committee, under the letter of approval 097/2009.
Results
In the one-year study period, there were 82,144 live
births in the 27 maternity hospitals participating in the
study and 9555 women received a diagnosis of SMM.
Severe hypertensive disorders were associated with 70%
of these hospital admissions (6706/9555), corresponding
to 81.6 cases per 1000 deliveries. Among the total num-
ber of women with severe hypertensive disorders, 94%
were classified as PLTC (6315/6706), while 349 cases
had organ dysfunction or failure, with prevalence of 4.2
NM cases per 1000 LB, a mortality index of 10.7% (42MD per 391 cases of NM plus MD), and the maternal
near miss to maternal death ratio was 8.3 NM cases to 1
MD (Table 1). The mortality was almost half of that for
non-hypertensive disorder conditions.
Table 2 highlights the percentage of approximately
20% of adolescents with SMM due to severe hyperten-
sive disorders, without any significant association with
severe maternal outcome. Age older than 40 years in-
creased the risk of SMO by almost 70% (PR 1.67; IC
1.21 – 2.31), which was not confirmed by multivariate
regression analysis. The risk of SMO decreased about
40% in women self-reported as non-white and in those
without a steady partner on hospital admission, but
these findings were not confirmed in the multivariate
analysis. Maternal history of some chronic diseases such
as kidney disease (PR 4.17; 2.49 – 6.98), connective tis-
sue disorders (PR 4.30; 2.16 – 8.56) and heart diseases
(PR 4.09; 2.18 – 7.64) increased around fourfold the risk
of SMO. The prevalence of chronic arterial hypertension
was 22.9% and of diabetes was 2.7% in the total number
of women with severe HD without significant associ-
ation with the outcome. History of heart disease was in-
dependently associated with a severe maternal outcome
by regression analysis (PRadj 1.98; 1.19 – 3.29).
Table 3 shows that during pregnancy and at the time
of hospital admission, healthcare insurance was mainly
provided by the Brazilian national public healthcare sys-
tem and this was not associated with severe maternal
outcome. Furthermore, the adequacy of prenatal care,
evaluated by the number of visits for each gestational
age, was appropriate in more than 70% of the total num-
ber of cases, with no association with SMO. Lower ges-
tational age at the time of hospital admission due to
severe hypertensive disorders (early onset of disease) and
also postpartum admission were strongly associated with
severe maternal outcome. In addition, women with
SMO had about twice the rate of elective Caesarean sec-
tions. Emergency access to an obstetric referral center
Table 2 Estimated risk of severe maternal outcome (SMO = NM+MD) among women with severe hypertensive
disorders during pregnancy or childbirth according to maternal characteristics, obstetric and medical history
Predictors % SMO PLTC PR 95% CI
Total n % n %
Age (years)
≤ 19 18.7 65 16.6 1186 18.8 0.98 0.77 – 1.25
20 – 29 46.9 167 42.7 2976 47.1 (ref)
30 – 39 29.6 130 33.2 1856 29.4 1.23 0.98 – 1.55
≥ 40 4.9 29 7.4 297 4.7 1.67 1.21 – 2.31
Skin color (a)
White 36.3 136 46.4 1623 35.7 (ref)
Non white 63.7 157 53.6 2927 64.3 0.66 0.48 – 0.91
Education (b)
Elementary 46.0 128 51.2 2162 45.7 1.23 0.88 – 1.73
> elementary 54.0 122 48.8 2566 54.3 (ref)
Marital status (c)
With partner 52.7 207 67.6 2783 51.8 (ref)
Without 47.3 99 32.4 2589 48.2 0.53 0.37 – 0.76
Number of pregnancies (d)
1 45.7 159 41.4 2893 45.9 0.91 0.72 – 1.16
2 – 3 37.0 141 36.7 2330 37.0 (ref)
4 or more 17.4 84 21.9 1076 17.1 1.27 1.00 – 1.61
Number of Childbirths (d)
0 52.4 178 46.4 3327 52.8 0.80 0.65 – 1.00
1 – 2 36.3 153 39.8 2270 36.0 (ref)
3 or more 11.3 53 13.8 702 11.1 1.11 0.76 – 1.63
Previous C-sections (e)
0 76.8 282 75.0 4797 76.9 (ref)
1 or more 23.2 94 25.0 1442 23.1 1.10 0.86 – 1.41
Medical history (f)
Chronic hypertension 22.9 92 28.0 1243 22,6 1.30 1.00 – 1.70
Diabetes 2.7 16 4.9 139 2.5 1.87 1.00 – 3.49
Kidney disease 1.3 17 5.2 58 1.1 4.17 2.49 – 6.98
Collagen disorders 0.4 6 1.8 19 0.3 4.30 2.16 – 8.56
Heart disease 1.5 19 5.8 67 1.2 4.09 2.18 – 7.64
Smoking 3.5 12 3.6 194 3.5 1.03 0.50 – 2.11
Total 391 6315
PR: prevalence ratio adjusted by cluster effect.
Missing data: (a) 1863 cases; (b) 1728 cases; (c) 1028 cases; (d) 23 cases; (e) 91 cases; (f) 888 cases.
Values in bold mean they are statistically significant.
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to three times higher in the SMO group; the diagnosis of
NM already existed in around 30% of cases at the time of
patient admission to study maternity hospitals (data not
shown in table). Most women with severe hypertensive
disorders suffered some kind of delay in receiving care
(55.6%) and these went to the second type, i.e. related to
the healthcare system (PR 2.86; 1.89 – 4.33) and thirdtype, those related to healthcare professionals (PR 2.45;
1.53 – 3.92) (Table 4).
Table 4 shows that other maternal complications (unless
thromboembolism) and procedures used for the manage-
ment of complications (unless the use of magnesium
sulphate), other than those already used for maternal near
miss case definition according to WHO [15], are signifi-
cantly more prevalent among cases of SMO than among
Table 3 Estimated risk of severe maternal outcome (SMO = NM+MD) among women with severe hypertensive
disorders during pregnancy or childbirth according to characteristics of current pregnancy and delays in obstetric care
Predictors Total SMO PLTC PR 95% CI
% n % n %
Prenatal coverage (a)
Public 92.7 291 90.7 4566 92.6 0.76 0.47 – 1.23
Other 7.3 30 9.3 351 7.1 (ref)
Prenatal adequacy (b)
No 23.6 84 21.9 1486 23.7 0.91 0.71 – 1.15
Yes 76.4 299 78.1 4771 76.3 (ref)
Hospitalization coverage (c)
Public 99.3 386 98.7 6269 99.4 0.53 0.17 – 1.66
Other 0.7 5 1.3 41 0.6 (ref)
Gestational age at hospital admission (d)
<22 1,5 12 3.1 86 1.4 5.06 2.60 – 9.82
22 – 27 4.9 35 288 4.6 4.47 2.53 – 7.92
28 – 33 20.7 111 28.9 1265 20.2 3.33 2.21 – 5.02
34 – 36 22.5 89 23.2 1409 22.5 2.45 1.59 – 3.79
≥37 47.2 76 19.8 3062 48.9 (ref)
Postpartum 3.2 61 15.9 152 2.4 11.82 7.59 – 18.43
Gestational age at delivery (e)
<22 0.5 3 0.9 30 0.5 3.23 1.13 – 9.28
22 – 27 3.0 27 7.8 172 2.8 4.83 2.72 – 8.57
28 – 33 17.5 110 31.8 1030 16.7 3.43 2.19 – 5.38
34 – 36 22.6 96 27.7 1380 22.3 2.31 1.57 – 3.41
≥37 51.8 95 27.5 3284 53.1 (ref)
Still pregnant 4.6 15 4.3 284 4.6 1.78 1.03 – 3.10
Mode of delivery (f)
C-section 74.8 309 79.8 4694 74.5 1.33 0.99 – 1.79
Other 25.2 78 20.2 1605 25.5 (ref)
Onset of labor (g)
Spontaneous 26.8 66 17.7 1716 27.4 (ref)
Induction 9.0 33 8.9 562 9.0 1.50 0.86 – 2.60
Elective C-section 59.0 254 68.3 3665 58.5 1.75 1.11 – 2.76
Abortion 0.6 4 1.1 37 0.6 2.63 1.05 – 6.59
Still pregnant 4.5 15 4.0 285 4.5 1.35 0.77 – 2.37
Access to referral center (h)
Not scheduled 10.2 69 18.4 576 9.7 2.98 1.62 – 5.47
Scheduled 46.4 207 55.3 2715 45.9 1.97 1.30 -2.97
Spontaneous 43.3 98 26.2 2628 44.4 (ref)
Delays
Women/family members (i) 39.9 146 44.9 2179 39.6 1.23 0.89 – 1.69
Health service (j) 16.2 129 35.6 874 15.0 2.86 1.89 – 4.33
Health professional (l) 19.1 132 36.6 1066 18.0 2.45 1.53 – 3.92
Any delays 55.6 256 73.6 3131 54.5 2.22 1.44 – 3.43
Total 391 100 6315 100
Values in bold mean they are statistically significant; PR = prevalence ratio adjusted by cluster effect.
Missing data: (a) 1468 cases; (b) 66 cases; (c) 5 cases; (d) 60 cases; (e) 180 cases; (f) 20 cases; (g) 69 cases; (h) 413; (i) 875 cases; (j) 513 cases; (l) 613 cases.
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Table 4 Other maternal complications and estimated risks of perinatal results of current pregnancy associated
with severe maternal outcomes (SMO = NM+MD) among women with severe hypertensive disorders during
pregnancy or childbirth
Variables % SMO PLTC p
Total n % n %
Maternal complication*
Placental abruption 3.6 37 9.5 207 3.3 <0.0001
Postpartum hemorrhage 4.0 74 18.9 196 3.1 <0.0001
Other severe hemorrhage 0.5 17 4.3 19 0.3 <0.0001
Pulmonary edema 1.7 65 16.6 48 0.8 <0.0001
Thromboembolism 0.2 2 0.5 9 0.1 0.2688
Sepsis 1.0 49 12.5 15 0.2 <0.0001
Procedures used for management* 79.4 384 98.2 4938 78.2 <0.0001
Blood transfusion 7.9 207 52.9 326 5.2 <0.0001
ICU admission 21.9 290 74.2 1178 18.7 <0.0001
Hospital stay >7days 30.7 253 64.7 1805 28.6 <0.0001
Invasive mechanical ventilation 1.8 116 29.7 2 0.0 <0.0001
Magnesium sulphate use 68.4 279 71.4 4309 68.2 0.2178
Perinatal results PR 95% CI
Apgar at 5 min <7 (a) 3.3 34 12.9 164 2.9 4.28 3.26 – 7.38
Apgar at 5 min ≥7 96.7 230 87.1 5505 97.1 (ref)
Birth weight <2500 g (b) 42.3 212 68.6 2388 40.9 2.98 2.10 – 4.22
Birth weight ≥2500 g 57.7 97 31.4 3447 59.1 (ref)
Stillbirth (c) 4.2 60 17.7 203 3.4 4.90 3.26 – 7.38
Live birth 95.8 279 82.3 5715 96.6 (ref)
Neonatal death (d) 2.4 11 4.2 124 2.3 2.50 1.35 – 4.60
NICU admission (d) 22.3 107 41.3 1172 21.4 2.56 1.53 – 4.28
Hospital discharge (d) 75.3 141 54.4 4179 76.3 (ref)
Total 391 100 6315 100
*excluded all near miss criteria according to WHO; risks are not estimated because they are not predictors nor outcomes.
p-values reported derive from Chi-square tests.
PR: prevalence ratio adjusted by cluster effect.
Missing data: (a) = 773 cases; (b) = 562 cases; (c) = 449 cases; (d) = 972 cases.
Values in bold mean they are statistically significant.
Zanette et al. Reproductive Health 2014, 11:4 Page 6 of 11
http://www.reproductive-health-journal.com/content/11/1/4cases of PLTC as they were obviously expected. Magne-
sium sulphate was used in a little more than two thirds of
the total number of cases (68.4%) and showed no signifi-
cant difference among groups. The risks of worse perinatal
results were higher, especially among SMO cases, with
13% of hypoxic newborns, almost 70% with low birth
weight and more than 40% were admitted to NICU. Peri-
natal mortality was 6.6%, with 21.9% versus 5.7% among
women with SMO compared to those with PLTC, re-
spectively (the sum of stillbirths plus neonatal deaths,
not showed in table).
In Table 5, Poisson multiple regression analysis identified
variables independently associated with severe maternal
outcomes cases: history of heart disease, acute pulmonary
edema, postpartum hemorrhage and early onset of disease
in relation to gestational age, or hypertension remote fromterm. Blood product transfusion, admission to ICU, inva-
sive mechanical ventilation non-related to anesthesia and
longer periods of hospitalization were highlighted as sig-
nificant management procedures associated with worse
outcome. Delays in obtaining adequate obstetric care were
also identified by difficulties linked to healthcare services
and health professionals.
Discussion
In this study, we applied the Near Miss criteria accord-
ing to WHO recommendation [15] to a group of women
with severe hypertensive disorders, following clinical
diagnoses of severe preeclampsia, eclampsia, HELLP
syndrome and severe arterial hypertension/hypertensive
emergency, justified by a greater specificity of these cri-
teria to case severity. Therefore, the capacity to identify
Table 5 Poisson multiple regression analyses with
variables independently associated with severe maternal
outcome (SMO = NM+MD; N = 5488*) among women
with severe hypertensive disorders during pregnancy or
childbirth
Variables PRadj 95% CI p
Clinical
Gestational age <37 weeks or
postpartum at hospital admission
1.73 1.22 – 2.44 0.003
Postpartum hemorrhage 1.60 1.28 – 2.00 <0.001
Pulmonary edema 1.86 1.24 – 2.82 0.005
Previous heart disease 1.98 1.19 – 1.59 0.029
Management
Blood transfusion 3.67 2.48 – 5.44 <0.001
Invasive mechanical ventilation 2.83 1.99 – 4.01 <0.001
ICU admission 3.75 2.06 – 6.82 <0.001
Hospital stay >7days 1.66 1.18 – 2.33 0.005
Delays
Delay: health system 1.60 1.19 – 3.29 0.010
Delay: health professional 1.28 1.03 – 1.59 0.029
PRadj = prevalence ratio adjusted by cluster effect and all other predictors
entering the model of Poisson multivariate regression analysis (maternal age,
skin color, education, marital status, number of pregnancies, number of
childbirths, previous C-sections, history of medical conditions, smoking,
prenatal coverage, prenatal adequacy, hospitalization coverage, gestational
age at hospital admission, gestational age at delivery, mode of delivery, onset
of labor, access to referral center, and delays).
*There were 1218 cases excluded due to at least one missing value for
variables entering the model
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organ dysfunction and/or failure was increased in this
group of women. We also performed the analysis of delays
after a systematic evaluation of data collected for interven-
tions that are beneficial to a reduction in morbidity and
mortality due to hypertension [23,24], such as the use of
magnesium sulphate and the collection of variables related
to obstetric care, such as patient access to referral centers,
among others. None of these results are “not already
known”, however the confirmation of these associations in
a large number of cases prospectively followed is import-
ant in establishing firm health care surveillance policies,
be it in hospitals, and especially if to be government re-
lated, wherever correspondent policies are being planned.
To increase the likelihood of identifying SMO markers
in this group of women, we conducted a multicenter
study in 27 referral maternity hospitals. Most of these
hospitals were public and rendered service by the Brazilian
national healthcare system. These maternity hospitals
were distributed in the five Brazilian regions and had at
least 1000 deliveries per year. With a prospective sur-
veillance system for identifying cases of severe maternal
morbidity admitted to hospital, it was possible to collect
data on all women and select those hospitalized due to
severe hypertensive disorder for this study. Our resultsshowed a rate of 81.6 SMM cases of severe hypertensive
disorders per 1000 LB. These numbers create demand
for hospital beds specialized in the management of these
conditions and corroborate the high prevalence of com-
plications that result in hospitalizations due to hyper-
tensive disorders in general [2,3].
With this method, we identified a prevalence of 4.2
NM cases due to severe hypertensive disorders per 1000
LB and a ratio of 8.3 cases of NM to 1 death, and mor-
tality index of 10.7%. This was much higher than those
found in high-income countries, which was 0 to 1.8%
[25-27] and in middle and low-income countries (0.5 to
20.7%) [12,28-31]. It is noteworthy that studies in high-
income countries used mainly clinical criteria for the
diagnosis of NM (severe preeclampsia, eclampsia and
HELLP syndrome). Studies of low-income countries se-
lected cases of organ dysfunction and/or failure among
clinical diagnoses and therefore used a method similar
to ours. In this study, a high ratio of specific maternal
mortality associated with hypertensive disorders was
found, with 51 deaths per 100.000 LB in these maternity
hospitals.
Among the maternal socio demographic, obstetric, and
clinical variables, older maternal age was identified as a
risk factor for severe maternal outcome, a finding that is
in agreement with results in the literature [32]. Some co-
morbid conditions that are relevant in studies investigat-
ing severe maternal morbidity are also associated with a
severe maternal outcome, not only for the hypertensive
disorder group [32]. Contrary to what has been reported
in the literature, non-white color, marital status and living
with a steady partner were variables associated with a
lower risk of SMO. Although the same findings were not
confirmed in the multivariate analysis, these results were
quite surprising. Anyway there are some arguments that
could possibly explain them: in Brazil, racial miscegen-
ation is high and race was dichotomously categorized as
white or non-white, which may have contributed to re-
duce differences between groups. Regarding marital status
however we found no answers and only identified in the
literature a qualitative study conducted in a low-income
country reporting a negative influence of partner and fam-
ily members on the woman’s decision to seek medical care
when she perceived symptoms [33]. Another possible ex-
planation for these findings could be a bias due to the
relatively high proportion of missing values for these vari-
ables. This occurred because the data was gathered after
discharge of the women and this information was not in
their clinical records. However we did not believe this is
very likely to be true, taking into account that a higher
proportion of missing values comes from less severe
(PLTC) than from NM or MD cases. On multivariate ana-
lysis, these variables did not show to be associated with se-
vere outcome. It is also important to consider that all
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picture, and this condition may have contributed to a
greater homogeneity between groups.
Among the obstetric variables, the most noteworthy is
early onset of hypertensive disease, evaluated by the
lowest gestational age at the time of admission. This
condition is recognized in the specific literature as a
predictor of poor maternal and perinatal prognosis
[18,34,35]. There is also an increased potential for the
presence of subclinical disease, such as systemic lupus
erythematous, kidney or thrombotic disease [35-38].
This condition remained an independent variable for se-
vere maternal outcome by multivariate analysis and was
confirmed as a marker of poor maternal and perinatal
prognosis, reinforcing recommendations of early admis-
sion to tertiary or referral centers, for adequate manage-
ment of the woman and fetus. In addition, assessment
of the best time for therapeutic delivery is warranted,
since it also results in a higher prevalence of preterm
birth and thus increased need for neonatal intensive
care therapy. In this study, preterm occurred in more
than 40% of the total number of newborn infants and
the prevalence was higher in the SMO group. This poor
perinatal outcome was in agreement with a population-
based study on the impact of hypertensive disorders in
perinatal mortality [39].
Among the clinical maternal variables identified by
Poisson multiple regression analysis, a history of heart
disease remained significantly associated with a severe
maternal prognosis. Studies conducted with pulmonary
artery catheterization showed that women suffering from
chronic arterial hypertension with superimposed pre-
eclampsia had a higher risk of developing pulmonary
edema [40] and also heart failure. Sibai suggested that
women with chronic arterial hypertension be evaluated
in the preconception period or at the beginning of preg-
nancy for the presence of target organ (heart, kidneys)
damage. These cases are termed “high-risk” and prenatal
care should be specialized to minimize maternal/perinatal
morbidity and mortality [41]. Chronic hypertension was
the major comorbid condition identified in around one-
fourth of the cases with severe hypertensive disorders.
Acute pulmonary edema is also a clinical marker of car-
diopulmonary complication. The pathophysiology of pre-
eclampsia favors the occurrence of this condition. Fluid
overload imposed on these women may increase the inci-
dence of pulmonary edema, especially during anesthetic
procedures and in the postpartum period [42] and that is
why fluid restriction is recommended (60 to 125 ml per
hour in 24 hours) in the management of severe pre-
eclampsia [43]. In our study, acute pulmonary edema was
prevalent in 1.7% of the total number of cases. Of these, it
occurred in 16.6% of the SMO group, while in only 0.8%
among patients with PLTC. Acute pulmonary edema hasalready been elected an indicator for quality assessment of
obstetric care in this group of women [44].
Regarding obstetric care, it is well-known that severe
hypertensive disorders, particularly eclampsia and hyper-
tensive emergency, predispose patients to the occurrence
of hemorrhagic or ischemic cerebral events, due to endo-
thelial dysfunction associated with the loss of cerebral
blood flow auto regulation that occurs in the presence of
eclamptic seizure or an abrupt elevation of blood pressure
levels. In the United Kingdom, a study on the incidence of
eclampsia and its complications reported a significant de-
crease in both conditions between 1992 and 2005, after
the introduction of magnesium sulphate for the manage-
ment of preeclampsia and eclampsia, with no maternal
death in 2005 [45]. We did not classify the clinical forms
of hypertension and therefore we could not evaluate the
use of magnesium sulphate in these cases.
Considering obstetric complications, there is a classic
association between severe hypertensive disorders and
placental abruption. However, there is no distinction in
the occurrence of postpartum hemorrhage. In our study
this complication was present in 4% of the total number
of cases, with 19% in the SMO group and 3% in the
group with PLTC. We believe that placental abruption
may represent an intermediate variable for the occur-
rence of postpartum hemorrhage, due to atony or uter-
ine apoplexy, which may also lead to an increased rate
of postpartum hysterectomy due to bleeding. However,
this affirmation could not be made because the associ-
ation between cases of placental abruption and uterine
atony was not analyzed. Studies have shown that the use
of magnesium sulphate in the antepartum care of these
cases decreases the occurrence of placental abruption
[6,46] and may reduce this morbid condition as well.
The need for interventions to manage severe disease
occurred in about 80% of these cases, with a clear pre-
dominance in the SMO group. Among them, mechanical
ventilation, blood product transfusion, admission in inten-
sive care units and also a longer period of hospitalization
were significantly associated with a worse prognosis.
These findings are in agreement with other national stud-
ies [47-49] and reinforce the need for obstetric intensive
care units for patient management.
Some delays for adequate obstetric care occurred in
more than half of the cases and in even a larger propor-
tion of SMO cases. Factors related to healthcare system
and services (second delay) and health professionals
(third delay) were associated with the worst outcomes.
These results unveil a fragmented care network, ineffi-
cient offices for regulation of obstetric beds and/or lack
of hospital beds for the management of complex cases
(obstetric intensive care units) and also a model of care
that disrespects scientific evidence on what is beneficial
for the treatment of hypertension, also evaluated by the
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70% for the total number of severe cases. These findings
are in agreement with publications about barriers
against the reduction in MD from hypertension, in low
or middle-income countries [8,23,44].
This study has some possible limitations. First, it was
not a population-based study, although it had represen-
tativeness in maternity hospitals in every region of the
country. Second, we did not classify the clinical forms of
severe hypertension, a fact that could allow us to identify
SMO by specific diagnosis, such as eclampsia which is
recognized as the major cause of maternal morbidity
and mortality in low-income and middle-income coun-
tries [1,6,9]. Classification of hypertension could also as-
sess management with magnesium sulphate in specific
clinical situations, since we believe that there was a low
prevalence of magnesium sulphate use (68%), consi-
dering that all cases were severe. This finding was simi-
lar to the results of another study on the prediction of
adverse outcome in preeclampsia, in which the preva-
lence of magnesium sulphate use was only 62% [34]. A
new international study from WHO has just showed that
magnesium sulphate was used in around 85% of cases of
eclampsia, therefore arising the discussion on the appro-
priateness and timing of use that would probably also
have a key role in determining the outcomes for women
[50]. Third, we failed to explore some relevant NM as-
pects by patient interview, due to technical impossibility
in obtaining a written informed consent term from all
women regardless of clinical condition presented at the
time of hospital admission. Nevertheless, it was possible
to perform analysis of the delays. In addition, and exactly
by this same reason, there are some variables like skin
color and education where missing data reached relatively
high proportions (around 25% of cases), thus possibly
favoring the occurrence of bias. However there is no
evidence that they were preferably distributed between
categories.
On the other hand, the merit of the study is its large
number of cases and the prospective surveillance using
standardized definitions recently adopted and recom-
mended by WHO. Poisson multiple regression analysis
could be performed in about 5500 cases to identify and/
or confirm clinical and obstetric markers independently
associated with worse maternal outcome, such as hyper-
tension remote from term, postpartum hemorrhage, his-
tory of heart disease and pulmonary edema, which may
be modified by direct intervention in patient care. Fur-
thermore, unpublished analysis of the delays identified
weaknesses in the national healthcare system, since tech-
nical, political and administrative interventions may
modify this predictor. Finally, we could not locate other
study addressing NM as defined by the WHO related
to HD. This reveals the possibility of implementing aprospective, hospital-based and national surveillance sys-
tem for the investigation of NM, particularly in hyper-
tension which is still the leading cause of maternal death
in Brazil.
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